^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

defactinib (VS-6063)

i
Other names: VS-6063, PF-04554878, PF-4554878
Company:
Verastem
Drug class:
FAK inhibitor
9d
Enrollment change
|
avutometinib (VS-6766) • defactinib (VS-6063)
10d
New P2 trial • Combination therapy
|
avutometinib (VS-6766) • defactinib (VS-6063)
29d
Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapy. (PubMed, Sci Transl Med)
Concomitant inhibition of both FAK (with VS-4718) and rapidly accelerated fibrosarcoma and MAPK kinase (RAF-MEK) (with avutometinib) induced tumor growth inhibition and increased survival across multiple PDAC mouse models. Combination of FAK and RAF-MEK inhibition alone improved antitumor immunity and priming of T cell responses in response to chemotherapy. These findings provided the rationale for an ongoing clinical trial evaluating the efficacy of avutometinib and defactinib in combination with gemcitabine and nab-paclitaxel in patients with PDAC and may suggest further paths for combined stromal and tumor-targeting therapies.
Journal • Stroma
|
KRAS (KRAS proto-oncogene GTPase) • MYC (V-myc avian myelocytomatosis viral oncogene homolog)
|
KRAS mutation
|
gemcitabine • albumin-bound paclitaxel • avutometinib (VS-6766) • defactinib (VS-6063) • VS-4718
1m
5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours (clinicaltrials.gov)
P1/2, N=182, Recruiting, Institute of Cancer Research, United Kingdom
New P1/2 trial • Combination therapy
|
BRAF (B-raf proto-oncogene)
|
temozolomide • avutometinib (VS-6766) • defactinib (VS-6063)
1m
P3 data • Journal
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS wild-type
|
avutometinib (VS-6766) • defactinib (VS-6063)
3ms
Preclinical evaluation of avutometinib and defactinib in high-grade endometrioid endometrial cancer. (PubMed, Cancer Med)
Avutometinib, defactinib, and to a larger extent their combinations, demonstrated promising in vitro and in vivo activity against EAC cell lines and xenografts. These preclinical data support the potential clinical evaluation of this combination in high-grade EAC patients.
Preclinical • Journal
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • ARID1A (AT-rich interaction domain 1A)
|
RAS mutation
|
avutometinib (VS-6766) • defactinib (VS-6063) • VS-4718
3ms
Exosomal CTHRC1 from cancer-associated fibroblasts facilitates endometrial cancer progression via ITGB3/FAK signaling pathway. (PubMed, Heliyon)
Overexpression of CTHRC1 in secreted exosomes promotes the metastatic ability of EC cells in mouse models and may be eliminated by Defactinib, an inhibitor of FAK Tyr397 phosphorylation. Moreover, overexpression of CTHRC1 was increased in EC patients, elevating with cancer progression, and correlated with negative tumor prognosis. Our results revealed that CAF mediated endometrial cancer progression is related to high levels of CTHRC1 and exosomal CTHRC1 derived from CAF may be a promising therapeutic strategy for metastatic endometrial cancer.
Journal
|
ITGB3 (Integrin Subunit Beta 3)
|
defactinib (VS-6063)
3ms
Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma (clinicaltrials.gov)
P1, N=12, Recruiting, Emory University | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2024 --> Oct 2025
Trial completion date • Trial primary completion date
|
avutometinib (VS-6766) • defactinib (VS-6063)
3ms
Enrollment open • Combination therapy • IO biomarker • Metastases
|
Opdivo (nivolumab) • avutometinib (VS-6766) • defactinib (VS-6063) • ABP 206 (nivolumab biosimilar)
4ms
Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma (clinicaltrials.gov)
P2, N=42, Recruiting, Washington University School of Medicine | Trial completion date: Dec 2026 --> Jun 2028 | Trial primary completion date: Dec 2025 --> Jun 2027
Trial completion date • Trial primary completion date • Metastases
|
defactinib (VS-6063)
4ms
New P2 trial • Combination therapy • IO biomarker • Metastases
|
Opdivo (nivolumab) • avutometinib (VS-6766) • defactinib (VS-6063) • ABP 206 (nivolumab biosimilar)
5ms
New P2 trial • Combination therapy • Metastases
|
avutometinib (VS-6766) • defactinib (VS-6063)
5ms
Injectable hybrid hydrogels enable enhanced combination chemotherapy and roused anti-tumor immunity in the synergistic treatment of pancreatic ductal adenocarcinoma. (PubMed, J Nanobiotechnology)
With only a single intratumoral injection, the combination treatment with erastin and defactinib produces further anti-tumor performance both in xenograft and KrasG12D-engineered primary PDAC mice and synergistically promotes the infiltration of CD8+ cytotoxic T cells and the reduction of type II macrophages. The findings may provide a novel promising strategy for the clinical treatment of PDAC.
Journal
|
KRAS (KRAS proto-oncogene GTPase)
|
defactinib (VS-6063) • erastin
6ms
Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer. (PubMed, Br J Cancer)
These results demonstrate that the epithelial-mesenchymal transition status may be a promising biomarker for the efficacy of combination therapy with avutometinib and defactinib in KRAS-mutated NSCLC.
Journal
|
KRAS (KRAS proto-oncogene GTPase)
|
avutometinib (VS-6766) • defactinib (VS-6063)
6ms
PTK2 is a potential biomarker and therapeutic target for EGFR- or TLRs-induced lung cancer progression via the regulation of the cross-talk between EGFR- and TLRs-mediated signals. (PubMed, Biomark Res)
Finally, therapeutic effects targeted to PTK2 in lung cancer in response to EGF and TLR agonists were verified by using its inhibitor (Defactinib). In summary, we identified that up-regulated PTK2 might be a reliable marker for EGFR- or TLRs-induced lung cancer progression in NSCLC patients via the regulation of the cross-talk between EGFR- and TLRs-mediated signaling. This study provides a theoretical basis for the therapeutic intervention of PTK2 targeting EGFR- or TLRs-induced lung cancer progression.
Journal • IO biomarker
|
EGFR (Epidermal growth factor receptor) • TYK2 (Tyrosine Kinase 2)
|
defactinib (VS-6063)
6ms
FBXO32 Stimulates Protein Synthesis to Drive Pancreatic Cancer Progression and Metastasis. (PubMed, Cancer Res)
Overall, this study uncovers a mechanism by which PDAC cells rely on FBXO32-mediated eEF1A1 activation to drive progression and metastasis. FBXO32 may serve as a promising biomarker for selecting eligible PDAC patients for treatment with defactinib.
Journal
|
EEF1A1 (Eukaryotic Translation Elongation Factor 1 Alpha 1) • FBXO32 (F-Box Protein 32) • ITGB5 (Integrin Subunit Beta 5)
|
defactinib (VS-6063)
7ms
Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma (clinicaltrials.gov)
P2, N=42, Recruiting, Washington University School of Medicine | Trial primary completion date: Dec 2026 --> Dec 2025
Trial primary completion date • Metastases
|
defactinib (VS-6063)
7ms
Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas. (PubMed, Gynecol Oncol)
The combination of avutometinib and defactinib demonstrates promising in vitro and in vivo anti-tumor activity against primary UCS cell lines and xenografts.
Preclinical • Journal • Combination therapy
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • MAP2K1 (Mitogen-activated protein kinase kinase 1)
|
RAS mutation
|
avutometinib (VS-6766) • defactinib (VS-6063) • VS-4718
7ms
New P2 trial
|
letrozole • avutometinib (VS-6766) • defactinib (VS-6063)
7ms
New P2 trial • Combination therapy • Metastases
|
Erbitux (cetuximab) • avutometinib (VS-6766) • defactinib (VS-6063)
8ms
EAY131-U: Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U) (clinicaltrials.gov)
P2, N=35, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2024 --> May 2025 | Trial primary completion date: May 2024 --> May 2025
Trial completion date • Trial primary completion date
|
NF2 (Neurofibromin 2)
|
NF2 mutation
|
defactinib (VS-6063)
8ms
Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer. (PubMed, Gynecol Oncol)
Avutometinib, and to a larger extent its combination with FAK inhibitor VS-4718, demonstrated promising in vivo activity against a KRAS wild-type LGSOC-PDX. These data support the ongoing registration-directed study (RAMP201/NCT04625270).
Preclinical • Journal • Combination therapy
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • ADRB2 (Adrenoceptor Beta 2) • PRKDC (Protein Kinase, DNA-Activated, Catalytic Subunit) • PTK2B (Protein Tyrosine Kinase 2 Beta)
|
KRAS mutation • BRAF mutation • KRAS wild-type • RAS wild-type
|
avutometinib (VS-6766) • defactinib (VS-6063) • VS-4718
8ms
Enrollment closed • Combination therapy
|
avutometinib (VS-6766) • defactinib (VS-6063)
9ms
Trial completion date
|
NF2 (Neurofibromin 2)
|
NF2 mutation
|
defactinib (VS-6063)
9ms
Enrollment open
|
NF1 (Neurofibromin 1) • RAS (Rat Sarcoma Virus)
|
BRAF V600E • BRAF V600K • BRAF wild-type • RAS mutation
|
Braftovi (encorafenib) • avutometinib (VS-6766) • defactinib (VS-6063)
9ms
Inhibitory Impact Of Cinobufagin In Triple-Negative Breast Cancer Metastasis: Involvements Of Macrophage Reprogramming Through Upregulated MME and Inactivated FAK/STAT3 Signaling. (PubMed, Clin Breast Cancer)
This study unveils CBG's ability to enhance MME expression, deactivate FAK/STAT3 signaling, and inhibit TNBC metastasis by suppressing M2-skewed macrophages.
Journal
|
MME (Membrane Metalloendopeptidase)
|
defactinib (VS-6063)
9ms
RAMP 203: Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients (clinicaltrials.gov)
P1/2, N=153, Recruiting, Verastem, Inc. | N=53 --> 153 | Trial completion date: Sep 2025 --> Apr 2027
Enrollment change • Trial completion date • Combination therapy
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12
|
Lumakras (sotorasib) • avutometinib (VS-6766) • defactinib (VS-6063)
9ms
Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma (clinicaltrials.gov)
P2, N=42, Recruiting, Washington University School of Medicine | Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Jun 2026 --> Dec 2026
Trial completion date • Trial primary completion date • Metastases
|
defactinib (VS-6063)
10ms
Integrin β4 Regulates Cell Migration of Lung Adenocarcinoma Through FAK Signaling. (PubMed, Mol Biotechnol)
Focal adhesion kinase (FAK) inhibitor defactinib was used to further explore the molecular mechanism of ITGB4...In addition, ITGB4 could interact with FAK in lung adenocarcinoma cells. ITGB4 may promote cell migration of lung adenocarcinoma through FAK signaling pathway and has the potential to be a biomarker for lung adenocarcinoma.
Journal
|
ITGB4 (Integrin Subunit Beta 4)
|
defactinib (VS-6063)
10ms
Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
P2, N=36, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
Trial completion date • Trial primary completion date
|
Keytruda (pembrolizumab) • defactinib (VS-6063)
10ms
RAMP-202: A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=90, Completed, Verastem, Inc. | Recruiting --> Completed | Trial completion date: Dec 2025 --> Dec 2023 | Trial primary completion date: Mar 2023 --> Aug 2023
Trial completion • Trial completion date • Trial primary completion date • Combination therapy
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
|
KRAS mutation • BRAF mutation • KRAS G12V • KRAS G12
|
avutometinib (VS-6766) • defactinib (VS-6063)
11ms
Annotation of CD8 T-cell function via ICAM-1 imaging identifies FAK inhibition as an adjuvant to augment the antitumor immunity of radiotherapy. (PubMed, Theranostics)
Mechanistically, VS-6063 overcomes the physical barriers in tumors and promotes the migration and infiltration of CD8 T cells primed by RT into distant tumors. Our findings highlight that molecular imaging of ICAM-1 levels provides a dynamic readout of the proliferation and effector function of tumor-infiltrating CD8 T cells, which facilitates the high-throughput exploitation of new combinational drugs to maximize the systemic antitumor effect of RT.
Journal
|
CD8 (cluster of differentiation 8) • ICAM1 (Intercellular adhesion molecule 1)
|
CD8 expression
|
defactinib (VS-6063)
11ms
New P1/2 trial
|
NF1 (Neurofibromin 1) • RAS (Rat Sarcoma Virus)
|
BRAF V600E • BRAF V600K • BRAF wild-type • RAS mutation
|
Braftovi (encorafenib) • avutometinib (VS-6766) • defactinib (VS-6063)
11ms
Trial completion date • Trial primary completion date • Metastases
|
avutometinib (VS-6766) • defactinib (VS-6063)
11ms
Enrollment open
|
paclitaxel • letrozole • pegylated liposomal doxorubicin • avutometinib (VS-6766) • anastrozole • topotecan • defactinib (VS-6063)
11ms
Trial completion date • Trial primary completion date
|
BRAF (B-raf proto-oncogene) • NF1 (Neurofibromin 1) • RAS (Rat Sarcoma Virus)
|
BRAF mutation • NF1 mutation • RAS mutation
|
avutometinib (VS-6766) • defactinib (VS-6063)
12ms
Phase classification
|
gemcitabine • albumin-bound paclitaxel • avutometinib (VS-6766) • defactinib (VS-6063)
1year
Evaluating the therapeutic effects of small molecule inhibitors of CDK4/6 and FAK in preclinical meningioma models (SNO 2023)
In vitro, cell viability and proliferation assays were used to test abemaciclib (CDK4/6 inhibitor), defactinib (FAK inhibitor) and VS-6766 (RAF/MEK inhibitor) as monotherapy and in combination...The efficacy of VS-4718 (in vivo formulation of defactinib) and abemaciclib were evaluated in a subcutaneous IOMM-lee meningioma model (having CDKN2A loss) in nude mice... Abemaciclib showed promising efficacy in preclinical meningioma xenografts with CDKN2A loss. Studies to evaluate these therapies in other orthotopic models are underway.
Preclinical
|
CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDK4 (Cyclin-dependent kinase 4)
|
Verzenio (abemaciclib) • avutometinib (VS-6766) • defactinib (VS-6063) • VS-4718
1year
FTO facilitates cancer metastasis by modifying the mA level of FAP to induce integrin/FAK signaling in non-small cell lung cancer. (PubMed, Cell Commun Signal)
Our current findings provided valuable insights into the role of FTO-mediated mA demethylation modification in NSCLC metastasis. FTO was identified as a contributor to NSCLC metastasis through the activation of the FAP/integrin/FAK signaling, which may be a potential therapeutic target for NSCLC. Video Abstract.
Journal
|
FTO (Alpha-Ketoglutarate-Dependent Dioxygenase FTO) • YTHDF2 (YTH N6-Methyladenosine RNA Binding Protein 2)
|
FTO expression
|
defactinib (VS-6063)
1year
20P.1113: Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma (clinicaltrials.gov)
P2, N=13, Active, not recruiting, Thomas Jefferson University | Recruiting --> Active, not recruiting | Trial completion date: Jul 2024 --> Jan 2025 | Trial primary completion date: Oct 2023 --> Apr 2024
Enrollment closed • Trial completion date • Trial primary completion date • Metastases
|
avutometinib (VS-6766) • defactinib (VS-6063)
1year
New P3 trial • Combination therapy
|
paclitaxel • letrozole • pegylated liposomal doxorubicin • avutometinib (VS-6766) • anastrozole • topotecan • defactinib (VS-6063)
1year
Focal adhesion kinase activation by calcium-dependent calpain is involved in chronic lymphocytic leukaemia cell aggressiveness. (PubMed, Br J Haematol)
Treatment with the FAK inhibitor Defactinib was able to induce apoptosis in CLL cells. In conclusion, the malignant phenotype in unfavourable-prognosis patients seems to be encouraged by the overexpression of cortactin and HS1, that, together with FAK, may be involved in a druggable pathogenetic pathway in CLL.
Journal
|
IGH (Immunoglobulin Heavy Locus) • LYN (LYN Proto-Oncogene Src Family Tyrosine Kinase) • CTTN (Cortactin)
|
IGH mutation
|
defactinib (VS-6063)